Neurozen Co.
Latest round
- Series A
Last raised
- Jul 2021
Total raised
- $2.7M
Investors
- 3
About Neurozen Co.
Based in Seoul, South Korea, and founded by CEOs Sunny Lee and Kunho Lee in 2015, Neurozen Co. develops AI-powered neuroimaging and genetic solutions for the risk assessment and early detection of Alzheimer’s disease. Risk assessment and early detection are crucial to helping target the disease before irreversible brain damage or mental decline has occurred. Neurozen Co. has an exclusive license to the largest Asian dementia cohort organized by the National Research Center for Dementia (NRCD). The company works with neuroscientists, radiologists, bioinformatics specialists, and dementia experts to develop unique and effective solutions for Alzheimer's disease. In 2021, Neurozen Co.1 billion in series A investment. The company provides detailed genetic analysis for accurate Alzheimer's disease risk assessment through AI-powered neuroimaging and genetic solutions called NeuroXRP Genetic Testing Service and NeuroXgen Alzheimer’s Risk Assessment Service.
Who invested in Neurozen Co.
3 investors across 1 round
See all investors in Neurozen Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 29, 2021
Amount
$2.7M
Investors
Questions about Neurozen Co.
Who invested in Neurozen Co.?
Neurozen Co. has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neurozen Co. raised?
Neurozen Co. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Neurozen Co. last raise money?
Neurozen Co.'s most recent round on record is a Series A, in Jul 2021.
What does Neurozen Co. do?
Based in Seoul, South Korea, and founded by CEOs Sunny Lee and Kunho Lee in 2015, Neurozen Co.
Where is Neurozen Co. headquartered?
Neurozen Co. is headquartered in Seoul, South Korea.
Which VCs invest in companies like Neurozen Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, Taibao Capital and Hengxu Capital back healthcare companies at Neurozen Co.'s stage. Their profiles are linked below.
VCs backing healthcare startups at Series A
Raising like Neurozen Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.